Table 1 Baseline characteristics of the study population and reasons for not using warfarin for those with CHA2DS2-VASc score ≥ 2

Age (years), mean ± SD

67.3 ± 11.3

Male gender, n (%)

1873 (58.2%)

Time after diagnosis of atrial fibrillation (years), mean ± SD

3.4 ± 4.4

 - New

74 (2.3%)

 - Paroxysmal

1001 (31.1%)

 - Persistent

623 (19.4%)

 - Permanent

1520 (47.2%)

History of heart failure, n (%)

875 (27.2%)

History of coronary artery disease, n (%)

505 (15.7%)

Devices, n (%)

330 (10.3%)

History of transient ischemic attack, n (%)

121 (3.8%)

History of ischemic stroke, n (%)

451 (14.0%)

Hypertension, n (%)

2183 (67.8%)

Diabetes mellitus, n (%)

777 (24.1%)

History of bleeding, n (%)

308 (9.6%)

 Antiplatelet

854 (26.5%)

  - Aspirin

761 (88.0%)

  - ADP/P2Y12 inhibitors

191 (22.2%)

 Anticoagulant

2422 (75.3%)

  - Warfarin

2202 (90.9%)

  - Direct thrombin inhibitor

80 (3.3%)

  - Factor Xa inhibitors

140 (5.8%)

 - 0

479 (14.9%)

 - 1

955 (29.7%)

 - 2

977 (30.4%)

 - 3

480 (14.9%)

 - 4

237 (7.4%)

 - 5

79 (2.5%)

 - 6

11 (0.3)

 - 0

207 (6.4%)

 - 1

419 (13.0%)

 - 2

674 (20.9%)

 - 3

736 (22.9%)

 - 4

589 (18.3%)

 - 5

365 (11.3%)

 - 6

163 (5.1%)

 - 7

51 (1.6%)

 - 8

13 (0.4%)

 - 9

1 (0%)

 - 0

458 (14.2%)

 - 1

1190 (37.0%)

 - 2

1067 (33.2%)

 - 3

403 (12.5%)

 - 4

84 (2.6%)

 - 5

15 (0.5%)

 - 6

1 (0%)

Main reasons for not using warfarin, n (%)

653 (20.3%)

 - Already taking anti-platelet drugs

174 (26.6%)

 - Patient preference

151 (23.1%)

 - Using NOACS

148 (22.7%)

 - Bleeding risk

90 (13.8%)

 - Physician preference

89 (13.6%)

 - Fall risk

27 (4.1%)

 - Warfarin compliance concern

22 (3.4%)

 - Taking medication contra-indicated or cautioned for use with Warfarin

6 (0.9%)

 - Allergy

1 (0.2%)